key: cord-0734538-x09y21ag authors: Bateman, James; Cox, Natasha; Rajagopala, Lavanya; Ford, Mark; Jasim, Muhamad; Mulherin, Diarmuid; Venkatachalam, Srinivasan; Douglas, Barbara; Hirsch, George; Sheeran, Tom title: COVID-19 vaccination advice via SMS-based video to improve vaccination uncertainty in at-risk groups date: 2021-05-27 journal: Lancet Rheumatol DOI: 10.1016/s2665-9913(21)00148-x sha: ed4a6c0edadefb9e36bac7e489dc44466e5d127e doc_id: 734538 cord_uid: x09y21ag nan COVID-19 continues to present challenges worldwide. In an attempt to tackle the disease, SARS-CoV-2 vaccines have been rapidly developed and vaccination programmes are being rolled out. Guidance from both the European Alliance of Associations for Rheumatology and the British Society for Rheumatology recommend that patients on immunosuppressive treatment should receive a SARS-CoV-2 vaccine. 1 Emerging data highlight the need for specialist advice to improve the uptake of COVID-19 vaccines in patients with autoimmune rheumatic diseases; evidence suggests that vaccine uptake in these patients can be improved by more than 20% with physician recom men dation, and it is increasingly recognised that timely specialist input is required. [2] [3] [4] Low confidence in vaccine safety has been the main factor that has hindered vaccine uptake in patients with rheumatic disease. 5 Previous work has shown the utility of mobile SMS for the rapid distribution of urgent health-care communications. 6 As such, we developed a multimedia video message focused on vaccine education that was distributed by mobile SMS messaging, a successful and well established method of analysis. Additionally, it is unclear if patients underwent standardised postoperative rehabilitation protocols, which can markedly influence postoperative outcomes. Additionally, the type of revision implant and extent of revision surgery required can also be difficult to fully capture using national registry data. Future studies can build on this work by specifically comparing revision knee replacement survivorship, taking into consideration bone loss and the type of revision prosthetics required to accommodate for this bone loss. For example, an increased need for constrained prostheses or augments might be associated with higher risks of re-revision and at shorter postoperative time points given that these supplemental prostheses are typically used when the native bony and soft tissue anatomy is insufficient, which can be a risk for early implant wear and failure. Nevertheless, the authors have presented one of the largest studies focused on revised and multiply revised total knee replacement survivor ship, which can provide the foundation for future research focused on these unanswered questions. We commend Deere and colleagues for their exhaustive study on postoperative outcomes in revision total knee replacement procedures. This study can help inform conversations between orthopaedic surgeons, as well as primary care physicians, and their patients who might be facing revision surgery. This study also discusses important timelines following a revision knee replacement procedure that could be predictive of the need for re-revision, which is a question often asked by patients. Overall, the data from Deere and colleagues' Article should help reassure patients regarding implant survivorship and provide physicians the needed data to better educate their patients who require revision knee replacements. For COVID-19 guidance from the British Society for Rheumatology see https:// www.rheumatology.org.uk/ practice-quality/covid-19guidance communication in our rheumatology follow-up cohort of more than 10 000 patients. 7 We developed an 8-min interactive web-based educational video that was designed for mobile phones. We included UK information on current licensed COVID-19 vaccines, vaccination scheduling, safety, frequently asked questions, and links to established resources. Videos were piloted with clinicians, our patient participation group, and a national charity. Videos were included as links in a SMS message and communicated to all patients who had a valid mobile phone number on our electronic patient administration system. To evaluate this intervention, patients were sent web-based evaluations by SMS, which also gathered data on sex, age, current medications, and diagnosis. We used the Likert scale on responses to evaluate patient perceptions of the video. Mean Likert scores were calculated, and comparisons were made between patients in different age, sex, and diagnostic groups. Evaluations were collected 14 days after distribution of the video; data were analysed using SPSS, version 27. Executive institutional approval confirmed that this service development and evaluation, using voluntary anonymous respondent data, did not require a formal ethics review. Additional consent is not required to send health-care SMS messages under EU General Data Protection Regulation. We sent the SMS messages containing the video link on Dec 21, 2020 to 8886 (of the 10 981) patients who had a valid mobile phone number on our system. After 14 days, we had 2358 video views (27%) and 661 patients completed the evaluation (appendix). Pre-intervention, 36% of patients aged 30-49 years reported being aware that the vaccine was safe and recommended for them, compared with 47% of patients aged 50-69 years and 52% of patients aged 70 years or older. The educational video significantly increased these percentages, to 88% in patients aged 30-49 years, 92% in patients aged 50-69 years, and 94% in those aged 70 years or older. We received no responses from recipients aged 18-29 years. Likert scores showed that patients felt better informed about the vaccine (mean score 4·1 on a scale of 1-5), were more confident about receiving the vaccine (4·2), learned more about the safety of the vaccine (4·2), and were more likely to seek vaccination (4·1) as a result of the interactive video. Responders thought the video was a helpful way to share information (4·4). Compared with patients in the 30-49 years age group, older patients learned significantly more about the vaccine (50-69 years: mean difference (MD) 0·4, p=0·003; ≥70 years: MD 0·4, p=0·002), were more confident about having the vaccine (50-69 years: MD 0·3, p=0·008; ≥70 years: MD 0·3, p=0·02), and were more likely to have the vaccine (50-69 years: MD 0·4, p=0·002; ≥70 years: MD 0·5, p=0·001). The results were not affected by sex or rheumatic disease diagnosis. These data show that our vaccine information video was highly effective at addressing misconceptions around vaccination and had the greatest effect in patients aged 70 years or older, who constitute an atrisk group. Whereas digital accessibility in older age groups was previously thought to be a barrier, our older cohorts appeared equally able to access health-care communications on their mobile phones, which perhaps reflects the shift to using digital technology in this age group in the general population. 7, 8 Patients completing the evaluation were generally representative of our patient population. Our youngest patients returned no evaluations, which might relate to a range of factors, including the suggested long wait for vaccination in this age group in the UK at the time of distribution of the video. Our patients reported lower confidence in vaccine safety when compared with other reported data. 2, 5 We acknow ledge that patients with limited digital accessibility will be missed out using this style of communication and that alternative provisions will be required; 9 further research exploring how best to engage with these rheumatology patient cohorts is needed. However, there is broad scope for the application of this technology in other groups of patients. There are several limitations of this work. We did not include a comparator group and, although we can hypothesise reasons for the differences in impact and response rates across our cohort, many factors might have influenced these differences, which require further investigation. In conclusion, to our knowledge, this is the first published intervention using a targeted COVID-19 vaccine education video and the first to be delivered to patients with autoimmune rheumatic diseases. Our findings echo those of others who have reported low awareness of vaccine information and safety. 2 Crucially, the oldest age group, which constitutes the most at-risk See Online for appendix population, found the video most informative and were more likely than those in younger age groups to change their behaviour as a result. This work adds to the evidence supporting SMS-linked technology in distributing target ed patient educational materials and its role in a pandemic. 6 Further research on vaccine uptake and imple men tation at regional and national levels could counter misinformation around vaccination programmes and help to save lives. We would like to thank our Patient Participation Group and the Hibbs Lupus Trust for their support, along with the clinical and nursing staff at both sites. Requests for access to the data should be made to the corresponding author. There was no funding source for this study. We declare no competing interests. Shutterstock When we launched The Lancet Rheumatology in 2019, a fundamental part of our mission was to use our pages to advocate for the improved lives of patients with rheumatic diseases around the globe. Helping to improve patients' lives requires an understanding of their needs and the ways in which science and medicine might be struggling to meet those needs. But 'unmet need' means different things to different people and different patient populations, driven by myriad factors including geographical location, socioeconomic factors, health literacy, and availability of and access to care (to name just a few). The reality of clinical research is that most studies and clinical trials are done in well-funded research institutes in high-income countries. Reflecting this, a majority of research Articles submitted to The Lancet Rheumatology are from authors in the UK, USA, and Europe; countries in South America and Africa are particularly underrepresented. Indeed, these trends are similar across many (if not most) research journals. A related problem is that patient populations included in clinical trials are highly selected and not always representative of all patients-issues that can adversely affect health equity. In an effort to gain insight into the many dimensions of unmet need across the globe, The Lancet Rheumatology is launching a Podcast Series featuring interviews with rheumatology specialists and clinical researchers working in a variety of settings and geographical regions worldwide, to get a first-hand view of the challenges they face and what unmet need means to them and their patients. As part of this project, we are seeking three guest editors-ideally early-career rheumatologists and researchers-to join The Lancet Rheumatology editorial team in conducting these interviews and also to lend their insights as clinicians and researchers. As with our interviewees, we are looking for guest editors working in a variety of clinical settings and from distinct geographical regions. If you are interested in collaborating with us on this exciting project and joining these illuminating conversations, please send your CV and a brief statement of interest to The Lancet Rheumatology at rheumatology@ lancet.com. The deadline for applications is July 15, 2021. We look forward to adding your voices to our own as we explore the challenges facing clinicians and patients across the globe. I declare no competing interests. Heather Van Epps h.vanepps@lancet.com European Alliance of Associations for Rheumatology. EULAR viewpoints on SARS-CoV-2 vaccination in patients with RMDs SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists Perspective of patients with autoimmune diseases on COVID-19 vaccination Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey Rapid distribution of information by SMS-embedded video link to patients during a pandemic Older adults' attitudes and barriers toward the use of mobile phones The 'new normal' for many older adults is on the internet. bloomberg.com COVID-19 and digital inequalities: reciprocal impacts and mitigation strategies